Merito is a platform enabling crowd investment in medical/biotech ventures in Japan and Taiwan. Merito brokers investment in the IP of these ventures via Sponsored Research Agreements (SRAs). Merito fills a critical gap in early-stage capital markets. Merito has onboarded over 28 projects from elite Japanese universities.

Merito upgrades deep tech funding to digital funding--an upgrade from the analog era that has been dominated by slow institutional grants and high administrative costs. Finally, innovators can access private capital from global sources for efficient angel investment fundraising. Merito makes Open Innovation frictionless and accessible. Merito turns scientific creativity into a liquid, investable asset class.
Merito's launch comes at a pivotal moment when deep tech funding remains stuck in the analog era—dominated by governments, slow institutional grants, and high administrative costs. Scientific innovators still struggle to access private capital. Angel rounds are inefficient, and science doesn't fit the traditional VC mold. But change is underway. Science funding now is being privately funded, making it frictionless and accessible through platforms like Merito. Under the expanding Open Innovation model, companies are sourcing IP from Merito's portfolio to drive their R&D. Merito is seizing a generational shift toward a market-driven model for academic-origin deep tech—turning scientific creativity into a liquid, investable asset class.

We are making deep tech more MERITOcratic.

Merito Network

Org chart

Teams

Offices